Fresenius Medical Care

Rank: 5
2015 Rank15
R&D Spend:$305,969,147
Fiscal year ending:12-31-15
Click here to see all 100

After a year of stagnating profit growth, Fresenius predicted bottom-line gains of 15% to 20% for its fiscal 2016 year. The German dialysis giant responded to the Affordable Care Act's emphasis on bundled payments and managed care by expanding its services offering, acquiring stakes in Cogent Healthcare and Sound Inpatient Physicians. Fresenius is aiming to build a $5 billion care-coordination business by 2020. In March 2014 Fresenius re-introduced its renal research branch, renaming it "Frenova" and reiterating the group’s commitment to developing novel therapies. -- Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.

Fresenius appoints Stephan Sturm as new Chief Executive Officer – Ulf Mark Schneider leaves the company to pursue another opportunity. Fresenius Kabi USA honored for helping disaster survivors. Fresenius Kabi acquires Ready-to-Administer Drugs and U.S. Pharmaceutical Plant from Becton Dickinson. Fresenius Kabi sells German oncology compounding business. Fresenius Kabi and Halyard Health enter Supply and Distribution Agreement for Halyard Health Elastomeric I.V. Infusion Pumps. Fresenius Kabi Receives FDA Status Upgrade for US Grand Island Facility.

2015 Top 500 Solar Contractors Key Personnel: Stephan Sturm, Chairman & CEO; Francesco De Meo, CEO, Fresenius Helios; Jürgen Götz, Chief Legal & Compliance Officer & Labor Relations Director; Mats Henriksson, CEO, Fresenius Kabi; Rice Powell, CEO, Fresenius Medical Care; Ernst Wastler, CEO Fresenius Vamed.;

Else-Kroener-Strasse 1
Bad Homburg vor der, Höhe